진통제 시장 : 약제 유형, 투여 경로, 처방 상황, 연령층, 적응증, 유통 채널별 - 세계 예측(2026-2032년)

The Analgesics Market is projected to grow by USD 71.82 billion at a CAGR of 6.91% by 2032.

Analgesics remain one of the most essential pharmaceutical categories because pain is among the leading reasons people seek medical care and a major driver of disability, productivity loss, and healthcare utilization. The category spans non-opioid analgesics such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, topical pain relievers, fixed-dose combinations, and adjuvant therapies used in neuropathic, inflammatory, cancer-related, and postoperative pain.

Demand is supported by population aging, the rising prevalence of musculoskeletal disorders, cancer-related pain, postsurgical recovery needs, and greater consumer reliance on over-the-counter pain management. At the same time, regulatory agencies, including the U.S. FDA and European Medicines Agency, continue to shape the category through opioid risk mitigation, pharmacovigilance requirements, acetaminophen hepatotoxicity warnings, and safety communications on NSAID cardiovascular, renal, and gastrointestinal risks.

Transformative Shifts in the Analgesics Landscape

The analgesics landscape is being reshaped by the shift from volume-led prescribing to evidence-based, risk-stratified pain management. Health systems are prioritizing multimodal pain care, opioid-sparing protocols, abuse-deterrent formulations, prescription drug monitoring, and stronger patient education to balance effective relief with safety.

Another major shift is the expansion of consumer-centric pain management. Digital pharmacies, e-commerce OTC channels, telehealth consultations, and private-label analgesics are changing how patients access common pain medications. Meanwhile, manufacturers are investing in differentiated delivery formats, including topical gels, transdermal systems, extended-release products, unit-dose packaging, and combination therapies that improve convenience, adherence, dosing accuracy, and targeted pain relief.

Cumulative Impact of Artificial Intelligence on Analgesics

Artificial intelligence is having a cumulative impact across the analgesics value chain, from target discovery and molecule screening to real-world safety monitoring. AI-enabled platforms can analyze genomic, proteomic, clinical, imaging, and claims data to identify pain pathways, stratify patients, and support faster development of non-opioid candidates for inflammatory, neuropathic, and postoperative pain.

In commercial and clinical settings, AI is improving supply planning, adverse-event signal detection, medication adherence programs, and prescribing decision support. For opioids and controlled analgesics, machine learning models are increasingly used to identify patterns associated with misuse, diversion, high-risk prescribing, duplicate therapy, and drug interactions, supporting safer pain management when governed by validated data, transparent algorithms, human oversight, and strong privacy controls.

Key Regional Insights for Analgesics

Asia-Pacific is expanding in strategic importance due to aging populations, higher diagnosis of chronic pain conditions, broader healthcare access, and strong generic manufacturing capacity in China and India. Japan and South Korea support demand through advanced pain clinics, high life expectancy, and established reimbursement systems, while Australia maintains stringent medicine scheduling and safety communications through national regulators. Across Southeast Asia, pharmacy modernization and essential-medicine policies continue to improve access to affordable analgesics.

North America remains a highly mature analgesics environment shaped by established OTC consumption, advanced specialty pain care, and strict opioid stewardship. The United States continues to be influenced by CDC opioid prescribing guidance, FDA risk evaluation and mitigation strategies, prescription drug monitoring programs, and a strong movement toward non-opioid and multimodal approaches, while Canada emphasizes prescription monitoring, harm-reduction policies, and access to evidence-based pain care.

Latin America shows growing demand for affordable analgesics, particularly in Brazil and Mexico, but performance is influenced by healthcare access gaps, currency volatility, informal out-of-pocket spending, and public-sector procurement dynamics. Europe is characterized by robust pharmacovigilance, reimbursement discipline, and regulatory oversight under national agencies and the European Medicines Agency, with Germany, France, Italy, Spain, and the United Kingdom emphasizing safe opioid use, generic penetration, and clinical guideline alignment.

The Middle East, especially GCC countries, is investing in hospital capacity, specialty care, regulated pharmacy channels, and e-prescribing infrastructure, which supports more formalized pain management pathways. Africa continues to face significant unmet need for pain relief and palliative care due to access, affordability, supply continuity, and controlled-medicine availability constraints documented by global health agencies, making essential analgesic availability a persistent public health priority.

Key Group Insights for Analgesics

Within ASEAN, analgesics adoption is supported by expanding urban healthcare access, pharmacy modernization, rising OTC utilization, and regulatory harmonization efforts that improve product quality and cross-border market entry. The GCC benefits from high healthcare investment, hospital expansion, centralized procurement, and digital health programs, creating opportunities for branded, specialty, and hospital-administered analgesics under increasingly structured regulatory oversight.

The European Union remains a quality- and safety-driven environment where pharmacovigilance, centralized and national regulatory procedures, health technology assessment, and pricing discipline influence analgesic adoption. BRICS economies are important because Brazil, Russia, India, China, and South Africa combine large patient pools with domestic manufacturing capabilities, pricing controls, essential-medicine policies, and public health priorities that favor affordable generics and reliable supply.

G7 markets lead in clinical guidelines, safety monitoring, innovation funding, regulatory science, and real-world evidence generation, making them pivotal for non-opioid analgesic development and responsible post-market surveillance. NATO member countries add a distinct demand dimension through military medicine, trauma care, rehabilitation, emergency preparedness, and supply resilience planning for essential pain management therapies used in civilian and defense healthcare systems.

Key Country Insights for Analgesics

The United States is defined by high analgesic utilization, active opioid risk controls, prescription drug monitoring, and strong demand for non-opioid alternatives. Canada follows similar safety priorities with provincial reimbursement dynamics and monitoring programs, while Mexico combines OTC growth with affordability-driven generic demand and expanding pharmacy access. Brazil supports analgesics through private pharmacy networks, public procurement, essential-medicine policies, and strong generic uptake across a large and diverse healthcare system.

In Europe, the United Kingdom emphasizes clinical guidance, cost-effective prescribing, and opioid stewardship, while Germany benefits from advanced reimbursement structures, strong pharmacy access, and established pharmacovigilance. France maintains strict medicine oversight and public reimbursement, Italy and Spain show consistent demand tied to aging populations and musculoskeletal conditions, and Russia remains a large market shaped by domestic production priorities, controlled pricing policies, and changing import dynamics.

China and India are central to access and global supply, with China expanding healthcare coverage, hospital capacity, and domestic innovation while India maintains a major role in generic active pharmaceutical ingredients and finished dosage forms. Japan has sustained analgesic demand from a super-aged population and advanced clinical pathways, Australia emphasizes strict scheduling, poison information, and consumer safety, and South Korea combines advanced healthcare infrastructure with rapid uptake of differentiated pain management products and digital health tools.

Actionable Recommendations for Analgesics Leaders

Industry leaders should prioritize non-opioid innovation, safety-focused lifecycle management, and evidence generation that demonstrates clinically meaningful pain relief, lower adverse-event burden, and improved patient adherence. Investment in topical, extended-release, abuse-deterrent, pediatric-appropriate, geriatric-friendly, and combination formulations can help manufacturers differentiate in crowded generic and OTC segments.

Organizations should strengthen pharmacovigilance, real-world evidence capabilities, and regulatory intelligence to respond quickly to safety signals, label changes, scheduling decisions, and reimbursement expectations. Commercial teams should tailor strategies by channel, with medical education for prescription analgesics, consumer trust-building for OTC brands, responsible claims management, and digital pharmacy partnerships where regulation permits.

Supply resilience is also critical. Leaders should diversify API sourcing, qualify multiple manufacturing sites, monitor controlled-substance compliance, strengthen serialization and anti-counterfeit controls, and maintain transparent quality systems to reduce disruption risk in essential pain medicines.

Research Methodology for Analgesics Analysis

This executive summary is based on a structured research methodology that combines secondary research, primary industry validation, and analytical triangulation. Sources include public health agencies, regulatory authorities, clinical guidelines, pharmacovigilance communications, peer-reviewed literature, trade data, essential-medicine lists, reimbursement references, and recognized healthcare databases.

The analysis evaluates analgesics by product class, route of administration, prescription status, end user, distribution channel, region, economic bloc, and priority country. Findings are validated through cross-source comparison and interpreted using market drivers, restraints, regulatory shifts, supply chain indicators, safety signals, and demand-side healthcare trends to ensure data-backed and decision-ready insight while avoiding unsupported estimates, sizing, share, or forecasting claims.

Conclusion: The Future of Analgesics

The analgesics market is essential, resilient, and increasingly shaped by safety, access, and innovation. While OTC demand and generic availability support broad patient reach, opioid stewardship, NSAID safety concerns, and acetaminophen toxicity risks require disciplined product management, responsible promotion, and transparent communication.

Future leadership will favor organizations that combine clinically differentiated pain relief with strong compliance, responsible commercialization, AI-enabled evidence generation, and region-specific access strategies. As healthcare systems continue moving toward multimodal and personalized pain management, analgesics manufacturers that align efficacy, safety, affordability, and supply reliability will be best positioned to meet patient and provider needs.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Analgesics Market, by Type of Drug

• 7.1. Non-Opioids
  • 7.1.1. Acetaminophen
  • 7.1.2. Non-Steroidal Anti-Inflammatory Drugs
  • 7.1.3. Salicylates
• 7.2. Opioids
  • 7.2.1. Codeine
  • 7.2.2. Fentanyl
  • 7.2.3. Hydrocodone
  • 7.2.4. Morphine
  • 7.2.5. Oxycodone

8. Analgesics Market, by Route of Administration

• 8.1. Intramuscular
• 8.2. Intravenous (IV)
• 8.3. Oral
  • 8.3.1. Capsules
  • 8.3.2. Tablets
• 8.4. Rectal
• 8.5. Topical
• 8.6. Transdermal

9. Analgesics Market, by Prescription Status

• 9.1. Over-The-Counter
• 9.2. Prescription

10. Analgesics Market, by Age Group

• 10.1. Pediatric
• 10.2. Adult
• 10.3. Geriatric

11. Analgesics Market, by Indication

• 11.1. Acute Pain
  • 11.1.1. Injury-related pain
  • 11.1.2. Postoperative pain
• 11.2. Chronic Pain
  • 11.2.1. Arthritis
  • 11.2.2. Back pain
  • 11.2.3. Cancer pain
  • 11.2.4. Neuropathic pain

12. Analgesics Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. Analgesics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Analgesics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Analgesics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AbbVie Inc.
• 17.3. Alembic Pharmaceuticals Ltd.
• 17.4. Amneal Pharmaceuticals LLC
• 17.5. Apotex Inc.
• 17.6. Assertio Holdings, Inc.
• 17.7. AstraZeneca PLC
• 17.8. Averitas Pharma, Inc.
• 17.9. Bausch Health Companies Inc.
• 17.10. Bayer AG
• 17.11. Bristol-Myers Squibb Company
• 17.12. C.H. Boehringer Sohn AG & Co. KG
• 17.13. Cipla Limited
• 17.14. Collegium Pharmaceutical, Inc.
• 17.15. CSPC Pharmaceutical Group
• 17.16. Dr. Reddy's Laboratories Ltd.
• 17.17. Eli Lilly and Company
• 17.18. Endo International plc
• 17.19. F. Hoffmann-La Roche Ltd.
• 17.20. GlaxoSmithKline plc
• 17.21. Grunenthal GmbH
• 17.22. Haleon plc
• 17.23. Heron Therapeutics, Inc.
• 17.24. Hikma Pharmaceuticals plc
• 17.25. Johnson & Johnson Services, Inc.
• 17.26. Lupin Limited
• 17.27. Mallinckrodt plc
• 17.28. Merck KGaA
• 17.29. Novartis AG
• 17.30. Pacira BioSciences, Inc.
• 17.31. Perrigo Company plc
• 17.32. Pfizer Inc.
• 17.33. Sanofi S.A.
• 17.34. Sun Pharmaceutical Industries Limited
• 17.35. Teva Pharmaceutical Industries Ltd.
• 17.36. Viatris Inc.